CD166 as Cancer Stem Cells Marker Based on Colorectal Cancer Location and Individual Characteristic
Abstract
Abstract. Colorectal cancer stem cells (CR-CSCS) are associated with a sub-population of colorectal cancer (CRC)with stem-cell properties that have s crucial role eith in chemotherapy resitance or in recurrency of CRC. CR0CSCs express high levels of CD166 in the colorectal; however, their expression, based on thespecific location of CRC and individual characteristics, remains unclear. The objecive of this study was to investigate the CD166 exppressionbased on the locationof the proximal colon, distal colon and rectum, and individual profile. This was a cross-sectional study performed at the Internal Medicine Department, Faculty of Medicine, Adam Malik General Hospital and affiliation hospital from September, 2018 to July, 2019. The CRC tissue was taken from colonoscopy biopsy and surgical resection of CRC patients that fulfilled inclusion and exclusion criteria and signed informed consent. We examined immunohistochemistry for analyzing the CD166 expression.
Of the 118 subjects, 69 (58.5%) them were males, and the expression of CD166 high and low level were 45 (38.1%) and 43 (36.4%), respectively. There were no significant differences in age, sex, and BMI between high and low-level CD166 expression. There was no significant difference in laboratory findings between high and low-level CD166 expression. Based on tumor location, CD166 expression was significantly higher at distal colon than at the rectum (p=0.047). CD166 expression was associated with tumor location, and not with gender, sex, and laboratory parameters.
Keywords: Colorectal cancer stem cell, CD 166, tumor location.
References
References
L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet Tieulent, A. Jemal, “Global cancer statistics,” 2012. CA Cancer J Clin. 2015; 65:87-108.
R. Effendi-YS, D. Efendi, L. B. Dairy, M. Sihombing, G. A. Siregar, and L. H. Zain, “Profile of Colorectal Cancer Patients in Endoscopic Unit At Dr. Pirngadi Hospital Medan,” in Indonesian Journal of Gastroenterology Hepatology and Digestive Endoscopy, 9(3):pp.75-78, 2008.
I.Rey, R. Effendi-YS, and L. H. Zain, “Comparison of CEA level among tumor location and histopathological findings in colorectal cancer,” Journal of Gastroenterology and Hepatology; 31 (Suppl. 3): pp. 200, 2016.
L. Song, Y. Li, B. He, Y. Gong, “Development of Small Molecules Targeting the Wnt Signaling Pathway in Cancer Stem Cells forthe Treatment of Colorectal Cancer,” in Clinical Colorectal Cancer, Vol. 14, No. 3: pp.133-45, 2015
A. G. Hansen, G. W. Swart, and A. Zijlstra, ALCAM: Basis Sequence: Mouse. AFCS Nat Mol Pages. 2011.
L. C. van Kempen, J. M. Nelissen, W. G. Degen, R. Torensma, U. H. Weidle, H. P. Bloemers, C. G. Figdor, and G. W. Swart, “Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction,” in J Biol Chem. 2001; 276:25783-25790.
M. Watatani, T. Yoshida, K. Kuroda, S. Ieda, and M. Yasutomi, “Allelic Loss of Chromosome 17p, Mutation of The P53 Gene, and Microsatellite Instability in Right and Left-Sided Colorectal Cancer,” in Cancer 77 (Suppl), pp. 1688-93, 1996.
R. Effendi-YS, L. H. Zain, G. A. Siregar, H. R. Lubis, H. A. Damanik, L. I. Laksmi, and J. Chrestella, “Adenomatous Polyposis Coli, Mismatch Repair, and Microsatellite Instability in Colorectal Cancer Based on Different Locations,” in Acta Med Indones-Indones J Intern Med, Vol 45 (4), pp. 275-283, October 2013
T. Aoyama, K. Kashiwabara, K. Oba, M. Honda, S. Sadahiro, C. Hamada, H. Maeda, S. Mayanagi, M. Kanda, J. Sakamoto, S. Saji, and T. Yoshikawa, “Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials,” in Cancer Medicine. 2017; 6(11): pp.2523-2530.
A. G. Hansen, T. J. Freeman, S. A. Arnold, A. Starchenko, C. R. Jones- Paris, M. A. Gilger, M. K. Washington, K. H. Fan, Y. Shyr, R. D. Beauchamp, and A. Zijlstra,“Elevated ALCAM shedding in colorectal cancer correlates with poor patient outcome,” in Cancer Res. 2013; 73:2955-2964.
Y. Kato, H. Nishihara, H. Mohri, H. Kanno, H. Kobayashi, T. Kimura, M. Tanino, S. Terasaka, and S. Tanaka, “The clinicopathological evaluation of cyclooxygenase-2 expression in meningioma: immunohistochemical analysis of 76 cases of low- and high-grade meningioma,” in The Japan Society of Brain Tumor Pathology. 2012, pp. 31: 23-30
W.Weichert, T. Knosel, J. Bellach, M. Dietel, and G. Kristiansen, “ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival,” in J Clin Pathol. 2004; 57:1160-1164.
M. Tachezy, H. Zander, F. Gebauer, A. Marx, J. T. Kaifi, J. R. Izbicki, and M. Bockhorn, “Activated leukocyte cell adhesion molecule (CD166)—its prognostic power for colorectal cancer patients,” inJ Surg Res. 2012; 177:e15-20.
S. Han, W. Yang, S. Zong, H. Li, S. Liu, W. Li, Q, Shi, and F. Hou, “Clinicopathological, prognostic and predictive value of CD166 expression in colorectal cancer: a meta-analysis,”in Oncotarget. 8(38):64373-384, 2017.
D. Horst, L. Kriegl, J. Engel, T. Kirchner, and A. Jung,“Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer,” in Cancer Invest. 2009; 27:844-850.
A. Lugli, G. Iezzi, I. Hostettler, M. G. Muraro, V. Mele, L. Tornillo, V. Carafa, G. Spagnoli, L. Terracciano, and I. Zlobec, ”Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer,” in Br J Cancer. 2010; 103:382-390.
P. Minoo, I. Zlobec, and M. Peterson, L. Terracciano, and A. Lugli, “Characterization of rectal, proximal and distal colon cancersbased on clinicopathological, molecular and protein profiles,” International Journal of Oncology 37: 707-718, 2010
A. Jedinak, S. Dudhgaonkara, and D. Slivaa, “Activated macrophages induce metastatic behavior of colon cancer cells,” in Immunobiology 215. 2010:pp. 242–249
C. Raggi, H. S. Mousa, M. Correnti, A. Sica, and P. Invernizzi, “Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies,” in Oncogene 35. 2015: pp. 671-682.
N. Caronni, B. Savino, and R. Bonecchia, “Myeloid cells in cancer-related inflammation,” Immunobiology. 2015: pp. 249-253
DOI: 10.24815/jks.v0i0.29626
Refbacks
- There are currently no refbacks.